INJECTABLE TREATMENTS |
Ellansé™: the next generation in biostimulatory dermal fillers
P
ast studies have shown that in many cases patient retention is often low with regard to
returning to the same physician for follow-up treatments with conventional dermal fillers. Many patients may shop around after an initial treatment session, in search of better products with longer lasting outcomes, as well as more cost-effective options. The Ellansé dermal filler Family delivers on all these fronts, paving the way for physicians to forge longer-lasting relationships with their patients.
Introducing the Ellansé dermal filler Family The Ellansé dermal filler Family (Ellansé-S, M, L, and E) is specifically designed by AQTIS Medical™ as part of a total customised solution in medical aesthetics. It is the first dermal filler family with the unique feature of tunable longevity. Ellansé™ is further differentiated with the characteristics of sustained performance and total bioresorbability
(STAT
Technology™). All members of the family are
composed of unique, totally smooth and spherical shaped polycaprolactone (PCL) microspheres, homogeneously suspended in a tailor-made aqueous carboxymethyl cellulose (CMC) gel-carrier. The Ellansé Family is scientifically designed to provide optimal safety, biocompatibility, durability options, efficacy and
ease of use in soft tissue augmentation. PCL is a well-known and approved soft medical material. It has an excellent safety profile and has been used in bioresorbable sutures and orthopaedic implants worldwide for decades. PCL is also used in a number of other European (CE-certified) and US Food and Drug Administration (FDA) approved bioresorbable medical devices. Extensive safety studies have been conducted on the implant formulation, including in vitro, pre-clinical and clinical testing. Results from these tests demonstrate that the entire Ellansé™ dermal filler Family is safe, biocompatible and shows excellent
performance characteristics.
Mode of action The mode of action is the same throughout the entire Ellansé™ Family owing to the uniformity of particle size and particle smoothness. On injection of Ellansé, the body's natural response to the implant is stimulated and, because of the optimum viscosity and elasticity of the gel-carrier, the wrinkles and folds undergo immediate physical correction. The gel-carrier (suspension medium for microspheres) is gradually resorbed over a period of weeks after treatment. In parallel, the perfectly smooth PCL-microspheres stimulate neo-collagenesis to replace the volume of the resorbed carrier. The PCL microspheres are
AQTIS Medical BV Tel: +31 30 253 1901 Email:
info@aqtismedical.com
Web:
www.aqtismedical.com and
www.ellanse.com
24 ❚ Product Portfolio |
prime-journal.com
SAFE PRODUCT COMPONENTS WITH A LONG SAFETY HISTORY Perfectly smooth
Totally spherical microparticles High quality scaffold
SEM picture
Light microscopy picture
Light microscopy: Histology 2-weeks post intradermal injection (rabbit)
21 months post-injection of Ellansé M, PSR staining, showing a newly-formed collagen matrix around the PCL microspheres
embedded in a 3-dimensional scaffold of new high quality collagen. This scaffold formation leads to extended correction effects and unique sustained performance.
The soft tissue augmentation
effect is maintained throughout the duration performance of Ellansé (Sustained Performance). This new collagen creates volume to correct the signs of facial ageing and produces a longer-lasting natural result, which feels like the patient’s own skin. The PCL microspheres fully bioresorb, controlled and predictably, into water-soluble products and are
then fully excreted through normal metabolic pathways as CO2
water (total bioresobability).
Polycaprolactone: total bioresorption The hydrolytic bioresorption of
PCL microspheres occurs in two predictable and controlled phases. The first phase follows a predictable first-order linear pattern, in which the initial mass and volume of the microspheres remain intact. This is the basis of Ellansé. During this phase the average length of the polymer chain in the microspheres continuously decreases with time
and
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76